2SEVENTY BIO INC (TSVT) Stock Fundamental Analysis
USA - NASDAQ:TSVT - US9013841070 - Common Stock
5 USD
+0.01 (+0.2%)
5 USD
0 (0%)
TSVT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. TSVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TSVT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TSVT had negative earnings in the past year.
In the past year TSVT has reported a negative cash flow from operations.
TSVT had negative earnings in each of the past 5 years.
TSVT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TSVT has a Return On Assets of -11.94%. This is amongst the best in the industry. TSVT outperforms 83.81% of its industry peers.
The Return On Equity of TSVT (-27.16%) is better than 79.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.94% | ||
| ROE | -27.16% | ||
| ROIC | N/A |
ROA(3y)-29.71%
ROA(5y)-33.2%
ROE(3y)-64.75%
ROE(5y)-87.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of TSVT (52.43%) is better than 77.22% of its industry peers.
In the last couple of years the Gross Margin of TSVT has declined.
The Profit Margin and Operating Margin are not available for TSVT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 52.43% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.09%
GM growth 5Y-10.87%
2. Health
2.1 Basic Checks
TSVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
TSVT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TSVT has been increased compared to 5 years ago.
TSVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -1.30, we must say that TSVT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.30, TSVT is in line with its industry, outperforming 59.07% of the companies in the same industry.
TSVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.3 |
ROIC/WACCN/A
WACC10.02%
2.3 Liquidity
TSVT has a Current Ratio of 4.67. This indicates that TSVT is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.67, TSVT perfoms like the industry average, outperforming 51.96% of the companies in the same industry.
A Quick Ratio of 4.67 indicates that TSVT has no problem at all paying its short term obligations.
TSVT has a Quick ratio (4.67) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.67 | ||
| Quick Ratio | 4.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 72.14% over the past year.
TSVT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -62.28%.
TSVT shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.09% yearly.
EPS 1Y (TTM)72.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-62.28%
Revenue growth 3Y-11.43%
Revenue growth 5Y-3.09%
Sales Q2Q%84.29%
3.2 Future
The Earnings Per Share is expected to grow by 20.56% on average over the next years. This is a very strong growth
Based on estimates for the next years, TSVT will show a quite strong growth in Revenue. The Revenue will grow by 12.75% on average per year.
EPS Next Y58.41%
EPS Next 2Y33.7%
EPS Next 3Y30.96%
EPS Next 5Y20.56%
Revenue Next Year42.31%
Revenue Next 2Y24.94%
Revenue Next 3Y18.14%
Revenue Next 5Y12.75%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TSVT. In the last year negative earnings were reported.
Also next year TSVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TSVT's earnings are expected to grow with 30.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.7%
EPS Next 3Y30.96%
5. Dividend
5.1 Amount
TSVT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5
+0.01 (+0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.58%
Inst Owner Change0%
Ins Owners4.73%
Ins Owner Change-726.88%
Market Cap266.15M
Revenue(TTM)37.86M
Net Income(TTM)-57247000
Analysts47.5
Price Target5.1 (2%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.06%
Min EPS beat(2)-36.88%
Max EPS beat(2)22.77%
EPS beat(4)2
Avg EPS beat(4)33.02%
Min EPS beat(4)-36.88%
Max EPS beat(4)168.1%
EPS beat(8)5
Avg EPS beat(8)20.21%
EPS beat(12)8
Avg EPS beat(12)15.79%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-44.21%
Min Revenue beat(2)-76.66%
Max Revenue beat(2)-11.76%
Revenue beat(4)0
Avg Revenue beat(4)-34.98%
Min Revenue beat(4)-76.66%
Max Revenue beat(4)-11.76%
Revenue beat(8)1
Avg Revenue beat(8)-19.01%
Revenue beat(12)3
Avg Revenue beat(12)2.13%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-23.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.4%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.03 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.26 | ||
| P/tB | 1.3 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.71
BVpS3.96
TBVpS3.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.94% | ||
| ROE | -27.16% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 52.43% | ||
| FCFM | N/A |
ROA(3y)-29.71%
ROA(5y)-33.2%
ROE(3y)-64.75%
ROE(5y)-87.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.09%
GM growth 5Y-10.87%
F-Score3
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 9.96% | ||
| Cap/Sales | 1.87% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.67 | ||
| Quick Ratio | 4.67 | ||
| Altman-Z | -1.3 |
F-Score3
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)114.29%
Cap/Depr(5y)126.28%
Cap/Sales(3y)13.55%
Cap/Sales(5y)17.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y58.41%
EPS Next 2Y33.7%
EPS Next 3Y30.96%
EPS Next 5Y20.56%
Revenue 1Y (TTM)-62.28%
Revenue growth 3Y-11.43%
Revenue growth 5Y-3.09%
Sales Q2Q%84.29%
Revenue Next Year42.31%
Revenue Next 2Y24.94%
Revenue Next 3Y18.14%
Revenue Next 5Y12.75%
EBIT growth 1Y54.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.95%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.06%
OCF growth 3YN/A
OCF growth 5YN/A
2SEVENTY BIO INC / TSVT FAQ
What is the ChartMill fundamental rating of 2SEVENTY BIO INC (TSVT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to TSVT.
Can you provide the valuation status for 2SEVENTY BIO INC?
ChartMill assigns a valuation rating of 1 / 10 to 2SEVENTY BIO INC (TSVT). This can be considered as Overvalued.
How profitable is 2SEVENTY BIO INC (TSVT) stock?
2SEVENTY BIO INC (TSVT) has a profitability rating of 2 / 10.